Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| aTYR PHARMA INCATYR · Entity 7233 | Director · President and CEO | February 03, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
aTYR PHARMA INC
Report date February 03, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,553 |
Ending reported balance
After 2026-02-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-03 · Exercise / conversion · Acquired 10,375 · Balance 157,298 F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-02-04 · Sale · Disposed 3,745 · Balance 153,553 F3: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-03 · Exercise / conversion · Disposed 10,375 · Balance 0 F2: Restricted stock units convert into common stock on a one-for-one basis. F4: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F4: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 4, 2026 19:17 UTC | aTYR PHARMA INC ATYR · Entity 7233 | SaleCommon Stock | 3,745 | $0.98 | $3,655.12 |
DisclosureSEC source: 0001193125-26-038007 · ownership.xml · nonDerivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,553 F3 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 19:17 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 10,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-038007 · ownership.xml · derivative · entry 3 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F4 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 19:17 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionCommon Stock | 10,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-038007 · ownership.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 17:46 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 1,500,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001193125-26-009161 · ownership.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 18:18 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 10,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013891 · ownership.xml · derivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,375 Underlying: Common Stock · 10,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 18:18 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionCommon Stock | 10,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013891 · ownership.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 16:07 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0000950170-25-004151 · ownership.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2035-01-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 8, 2025, such that this option will be fully exercisable on January 8, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 08:34 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 20,000 | $1.81 | $36,140.00 |
DisclosureSEC source: 0000950170-24-067666 · ownership.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,548 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.77 to $1.86 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 20:20 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 10,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002949 · doc4.xml · derivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,750 Underlying: Common Stock · 10,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 20:20 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 10,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002949 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 19:35 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-24-001302 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2034-01-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 5, 2024, such that this option will be fully exercisable on January 5, 2028. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| December 12, 2023 Filed Dec 12, 2023 18:50 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 12,000 | $1.18 | $14,136.00 |
DisclosureSEC source: 0001209191-23-058377 · doc4.xml · nonDerivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,173 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.175 to $1.18 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 18:50 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 3,000 | $1.17 | $3,510.00 |
DisclosureSEC source: 0001209191-23-058377 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,173 Read SEC document |
| November 13, 2023 Filed Nov 13, 2023 16:11 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 13,578 | $1.11 | $15,085.16 |
DisclosureSEC source: 0001209191-23-054976 · doc4.xml · nonDerivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,173 F2 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.09 to $1.13 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 16:11 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 1,422 | $1.14 | $1,618.24 |
DisclosureSEC source: 0001209191-23-054976 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,595 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.13 to $1.14 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:07 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 15,000 | $2.01 | $30,223.50 |
DisclosureSEC source: 0001209191-23-043943 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,173 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $2.01 to $2.02 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 17:08 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 336,096 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-23-011282 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,096 Underlying: Common Stock · 336,096 shares Expires 2033-02-16 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 16, 2023, such that this option will be fully exercisable on February 16, 2027. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 18:57 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 10,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007362 · doc4.xml · derivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,125 Underlying: Common Stock · 10,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 18:57 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 10,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-007362 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:04 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 10,000 | $2.14 | $21,405.00 |
DisclosureSEC source: 0001209191-22-058295 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,798 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $2.13 to $2.16 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 17:02 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 15,000 | $2.88 | $43,164.00 |
DisclosureSEC source: 0001209191-22-041230 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,798 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $2.86 to $2.89 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price Read SEC document |
| May 24, 2022 Filed May 26, 2022 16:30 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 516,280 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-032204 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,280 Underlying: Common Stock · 516,280 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 24, 2022, such that this option will be fully exercisable on May 24, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 16:52 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Units · Derivative | 41,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007485 · doc4.xml · derivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 16:52 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001209191-22-007485 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 20:03 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 5,000 | $6.76 | $33,806.50 |
DisclosureSEC source: 0001209191-22-002768 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,798 Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 18:56 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 2,500 | $8.58 | $21,437.50 |
DisclosureSEC source: 0001209191-21-064565 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,798 Read SEC document |
| May 21, 2021 Filed May 25, 2021 21:03 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (Right to buy) · Derivative | 207,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001209191-21-035831 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 Underlying: Common Stock · 207,000 shares Expires 2025-05-21 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 21, 2021, such that this option will be fully exercisable on May 21, 2025. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| May 18, 2021 Filed May 20, 2021 08:52 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 10,000 | $4.01 | $40,100.00 |
DisclosureSEC source: 0001209191-21-034292 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,298 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $3.99 to $4.04 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 21:12 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon stock | 778 | $7.66 | $5,959.48 |
DisclosureSEC source: 0001209191-21-009112 · doc4.xml · nonDerivative · entry 2 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,298 F3 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019. Read SEC document |
| February 06, 2021 Filed Feb 9, 2021 21:12 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 1,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009112 · doc4.xml · derivative · entry 3 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. F4 · derivative.expiration_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. Read SEC document |
| February 06, 2021 Filed Feb 9, 2021 21:12 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 1,785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009112 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:18 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001209191-21-008634 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 4, 2021, such that this option will be fully exercisable on February 4, 2025. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 04, 2021 Filed Mar 9, 2021 16:29 UTC Amendment | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 112,469 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001209191-21-018992 · doc4a.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,469 Underlying: Common Stock · 112,469 shares Expires 2031-02-04 F1 · shares: The option grant was originally intended for 120,000 shares. However, that size of grant was in excess of an annual grant limit in the Issuer's equity plan and, as a result, the portion of the award that was in excess of the plan limit was disgorged. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 4, 2021, such that this option will be fully exercisable on February 4, 2025. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:23 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 6,000 | $4.27 | $25,620.00 |
DisclosureSEC source: 0001209191-20-038463 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,291 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $4.21 to $4.30 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:17 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001209191-20-032780 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2030-05-26 F1 · derivative.exercise_date: 50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020. Read SEC document |
| May 26, 2020 Filed Mar 9, 2021 16:23 UTC Amendment | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 73,142 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001209191-21-018977 · doc4a.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,142 Underlying: Common Stock · 73,142 shares Expires 2030-05-26 F1 · shares: The option grant was originally intended for 80,000 shares. However, that size of grant was in excess of an annual grant limit in the Issuer's equity plan and, as a result, the portion of the award that was in excess of the plan limit was disgorged. F2 · derivative.exercise_date: 50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020. Read SEC document |
| February 07, 2020 Filed Feb 7, 2020 19:37 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon stock | 745 | $4.03 | $3,002.35 |
DisclosureSEC source: 0001209191-20-007719 · doc4.xml · nonDerivative · entry 2 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291 F3 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 19:37 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 1,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007719 · doc4.xml · derivative · entry 4 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,786 Underlying: Common Stock · 1,786 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019. F5 · derivative.exercise_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. F5 · derivative.expiration_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 19:37 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 1,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-007719 · doc4.xml · nonDerivative · entry 1 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 19:37 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 39,327 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001209191-20-007719 · doc4.xml · derivative · entry 3 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,327 Underlying: Common Stock · 39,327 shares Expires 2030-02-05 F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 5, 2020, such that this option will be fully exercisable on February 5, 2024. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 19:09 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008750 · doc4.xml · derivative · entry 2 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs are scheduled to vest in two equal annual installments beginning on February 6, 2020, such that the RSUs will fully vest on February 6, 2021. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs are scheduled to vest in two equal annual installments beginning on February 6, 2020, such that the RSUs will fully vest on February 6, 2021. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 19:09 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-19-008750 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2019, such that this option will be fully exercisable on February 6, 2023. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 20:51 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-18-008629 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-02-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 13:56 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001209191-17-059076 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-11-01 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning December 1, 2017, such that this option will be fully exercisable on November 1, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:36 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009100 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 18:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141654 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.